Official Title: “Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA”

To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study

Study Primary Completion Date: April 2004

Intervention(s) in this Clinical Trial

• Drug: Celecoxib
  • Higher dose, 6 mg/kg/dose BID
• Drug: Celecoxib
  • Active drug at lower dose
• Drug: Naproxen
  • Control comparator, 15 mg/kg/dy target dose

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: High Dose
• Experimental: Low Dose
• Active Comparator: Naproxen
  • Control comparator, 15 mg/kg/dy target dose

Primary Measures

• ACR Pediatric 30
  • Time Frame: 12 weeks
    Safety Issue?: No

Secondary Measures

• Peds QOL
  • Time Frame: 12 weeks
    Safety Issue?: No
• composites of acr 30
  • Time Frame: 12 weeks
    Safety Issue?: No

Inclusion Criteria:

• 2-18 years old with active JRA

Exclusion Criteria:

• other experimental meds, recent changes in arthritis meds

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 2 Years

Maximum Age for this Clinical Trial: 18 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Pfizer

Overall Clinical Trial Officials and Contacts

Pfizer CT.gov Call Center Study Director Pfizer  

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00652925

Study ID Number: N49-01-02-195

ClinicalTrials.gov Identifier: NCT00652925

Health Authority: United States: Food and Drug Administration

To obtain contact information for a study center near you, click here.

Link to ClinicalStudyResults.org posting: